Related Articles
Shenzhen-based unicorn’s expanded focus to materials science aligns with a key strategic priority for China, as the industry is expected to reach 10 trillion yuan (US$1.48 trillion) by 2025.
Source link
Tags AI AI drug discovery automation big data biotech ChiaTai Tianqing Pharmaceutical Holdings Chinese unicorns CK Life Sciences Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone Hong Kong biotech Johnson & Johnson new materials Pfizer Pharmaceuticals Raw materials robotics Sequoia Capital Sino Biopharmaceutical Softbank Tencent XtalPi
About admin
Check Also
Women drive fast train to Mecca as Saudi workforce evolves
Rules introduced in recent years barring workplace gender discrimination and easing dress code restrictions have …
